Published in J Nucl Med on January 01, 2006
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. Nano Lett (2008) 2.01
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem (2009) 1.88
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J (2008) 1.67
Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem (2007) 1.64
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol (2012) 1.56
Near-infrared-labeled peptide multimer functions as phage mimic for high affinity, specific targeting of colonic adenomas in vivo (with videos). Gastrointest Endosc (2012) 1.55
18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging (2007) 1.49
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
PET Imaging of Integrin αVβ3 Expression. Theranostics (2011) 1.41
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging (2006) 1.39
Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res (2009) 1.38
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem (2009) 1.36
Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging (2009) 1.35
Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging (2012) 1.34
Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging (2012) 1.33
Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett (2007) 1.30
(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging (2009) 1.28
PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging (2012) 1.25
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics (2011) 1.25
Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol (2012) 1.22
(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem (2009) 1.19
Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med (2008) 1.19
Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem (2008) 1.18
Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med (2007) 1.16
Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging (2010) 1.15
Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes. Angew Chem Int Ed Engl (2009) 1.14
Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. J Mol Biol (2008) 1.12
Positron emission tomography imaging of prostate cancer. Amino Acids (2009) 1.11
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med (2008) 1.09
MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides. Mol Imaging Biol (2011) 1.08
Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res (2009) 1.05
Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS One (2012) 1.05
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics (2016) 1.02
Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol (2011) 1.02
Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Mol Imaging (2010) 1.01
2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem (2009) 1.01
Differential diagnosis of solitary pulmonary nodules using ⁹⁹mTc-3P₄-RGD₂ scintigraphy. Eur J Nucl Med Mol Imaging (2011) 1.01
Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer. Bioconjug Chem (2007) 1.00
A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem (2010) 1.00
An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem (2009) 0.98
Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. Phys Med Biol (2012) 0.98
99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging (2009) 0.97
Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics (2011) 0.95
PET Imaging of Angiogenesis. PET Clin (2009) 0.94
Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model. Mol Imaging Biol (2012) 0.94
Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging (2010) 0.93
PET of malignant melanoma using 18F-labeled metallopeptides. J Nucl Med (2009) 0.93
Molecular imaging of vessels in mouse models of disease. Eur J Radiol (2009) 0.92
Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconjug Chem (2010) 0.92
Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. Mol Imaging Biol (2013) 0.90
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by (18)F-labeled Arg-Gly-Asp positron-emission tomography. Circ Cardiovasc Imaging (2013) 0.89
Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency. Bioconjug Chem (2011) 0.88
Strain-Promoted Catalyst-Free Click Chemistry for Rapid Construction of (64)Cu-Labeled PET Imaging Probes. ACS Med Chem Lett (2012) 0.87
FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues. Bioconjug Chem (2014) 0.87
RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. Cancers (Basel) (2012) 0.87
Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins. Bioconjug Chem (2015) 0.86
Peptide heterodimers for molecular imaging. Amino Acids (2010) 0.86
Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe. Theranostics (2012) 0.86
Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Phys Med Biol (2015) 0.85
Biodistribution of the (18)F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. Eur J Nucl Med Mol Imaging (2015) 0.85
[¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. Eur J Nucl Med Mol Imaging (2014) 0.84
Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging (2009) 0.84
Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson (2010) 0.84
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging (2010) 0.84
Functional mutation of multiple solvent-exposed loops in the Ecballium elaterium trypsin inhibitor-II cystine knot miniprotein. PLoS One (2011) 0.84
Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen. Biomark Insights (2008) 0.84
Ultrasound molecular imaging of tumor angiogenesis with a neuropilin-1-targeted microbubble. Biomaterials (2015) 0.83
Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging (2010) 0.83
A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids (2010) 0.83
Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. PLoS One (2013) 0.82
Imaging the glycosylation state of cell surface glycoproteins by two-photon fluorescence lifetime imaging microscopy. Angew Chem Int Ed Engl (2013) 0.82
Applications of molecular imaging. Prog Mol Biol Transl Sci (2010) 0.81
PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. Curr Comput Aided Drug Des (2008) 0.81
Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor. Eur J Nucl Med Mol Imaging (2014) 0.79
Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Mol Pharm (2014) 0.79
F-18 Labeled RGD Probes Based on Bioorthogonal Strain-Promoted Click Reaction for PET Imaging. ACS Med Chem Lett (2015) 0.79
N-Succinimidyl 4-[(18)F]-fluoromethylbenzoate-labeled dimeric RGD peptide for imaging tumor integrin expression. Amino Acids (2011) 0.78
Evaluation of two novel (64)Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ3. Eur J Nucl Med Mol Imaging (2015) 0.78
A high-sensitivity small animal SPECT system. Phys Med Biol (2009) 0.78
Turning the tide in lung cancer. Nat Biotechnol (2010) 0.78
Atherosclerotic plaque uptake of a novel integrin tracer ¹⁸F-Flotegatide in a mouse model of atherosclerosis. J Nucl Cardiol (2014) 0.77
Effects of integrin-targeted photodynamic therapy on pancreatic carcinoma cell. World J Gastroenterol (2013) 0.77
Practical method for radioactivity distribution analysis in small-animal PET cancer studies. Appl Radiat Isot (2008) 0.77
Combination of an Integrin-Targeting NIR Tracer and an Ultrasensitive Spectroscopic Device for Intraoperative Detection of Head and Neck Tumor Margins and Metastatic Lymph Nodes. Tomography (2016) 0.76
Hybrid PET/optical imaging of integrin αVβ3 receptor expression using a (64)Cu-labeled streptavidin/biotin-based dimeric RGD peptide. EJNMMI Res (2015) 0.76
Exploration of peptide T7 and its derivative as integrin αvβ3-targeted imaging agents. Onco Targets Ther (2015) 0.75
Tetraspecific ligand for tumor-targeted delivery of nanomaterials. Biomaterials (2014) 0.75
Novel Method for Radiolabeling and Dimerizing Thiolated Peptides Using (18)F-Hexafluorobenzene. Bioconjug Chem (2015) 0.75
Comparison of the accuracy of (99m)Tc-3P4-RGD2 SPECT and CT in diagnosing solitary pulmonary nodules. Oncol Lett (2016) 0.75
Integrins: bidirectional, allosteric signaling machines. Cell (2002) 36.25
Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science (2002) 7.87
Definition of two angiogenic pathways by distinct alpha v integrins. Science (1995) 6.00
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med (1998) 3.85
Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation (2003) 3.15
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation (2003) 2.67
Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol (2000) 2.58
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res (2004) 2.46
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol (2004) 2.18
MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 2.15
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol (2004) 1.99
VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A (2005) 1.84
Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging (2004) 1.76
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol (2004) 1.72
Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets (2003) 1.70
Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging (2004) 1.64
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging (2004) 1.60
Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des (2004) 1.59
Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol Imaging (2004) 1.49
Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol (2004) 1.41
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem (2005) 1.34
Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis (1998) 1.29
A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol (2003) 1.27
Integrins: regulators of tissue function and cancer progression. Curr Pharm Des (2005) 1.08
Sodium dodecyl sulfate-stable complexes of echistatin and RGD-dependent integrins: a novel approach to study integrins. Mol Pharmacol (2000) 1.02
New insight into the analysis of 6-[18F]fluoro-L-DOPA PET dynamic data in brain tissue without an irreversible compartment: comparative study of the Patlak and Logan analyses. Radiat Med (2003) 0.81
Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev (2003) 11.29
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Self-illuminating quantum dot conjugates for in vivo imaging. Nat Biotechnol (2006) 4.60
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol (2008) 4.43
Molecular imaging in drug development. Nat Rev Drug Discov (2008) 4.06
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat Med (2009) 3.58
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) (2011) 3.33
Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res (2004) 3.16
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One (2008) 2.85
Teamwork in the operating room: frontline perspectives among hospitals and operating room personnel. Anesthesiology (2006) 2.78
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev (2012) 2.76
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopy. Proc Natl Acad Sci U S A (2009) 2.71
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature (2013) 2.67
The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell (2011) 2.65
Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol (2008) 2.61
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. Circulation (2003) 2.37
Molecular optical imaging with radioactive probes. PLoS One (2010) 2.36
Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res (2003) 2.36
Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology (2010) 2.32
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
Noninvasive cell-tracking methods. Nat Rev Clin Oncol (2011) 2.26
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation (2007) 2.21
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
Nanochannel electroporation delivers precise amounts of biomolecules into living cells. Nat Nanotechnol (2011) 2.10
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med (2011) 2.07
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res (2012) 1.97
Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler Thromb Vasc Biol (2011) 1.93
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc (2008) 1.89
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology (2008) 1.88
Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology (2008) 1.88
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med (2002) 1.86
FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol (2005) 1.86
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther (2006) 1.81
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol (2009) 1.79
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Quantum dot imaging for embryonic stem cells. BMC Biotechnol (2007) 1.78
Unusual magnetic properties of one-dimensional molecule-based magnets associated with a structural phase transition. Inorg Chem (2002) 1.78
Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest (2007) 1.78
Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation (2006) 1.75
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. Circ Res (2012) 1.74
Rad52-mediated DNA annealing after Rad51-mediated DNA strand exchange promotes second ssDNA capture. EMBO J (2006) 1.72
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70